WILEX AG announces results of Phase III ARISER study with RENCAREX® in clear cell renal cell carcinoma
WILEX AG (ISIN DE0006614720 / WL6 / FSE) today announced results of the Phase III ARISER trial with RENCAREX® (INN: Gire…
WILEX AG (ISIN DE0006614720 / WL6 / FSE) today announced results of the Phase III ARISER trial with RENCAREX® (INN: Gire…